By Sabela Ojea
ADC Therapeutics SA and Swedish Orphan Biovitrum said Friday that a European Medicines Agency committee has recommended granting marketing authorization for their co-developed Zynlonta drug, aimed at treating patients with diffuse large b-cell lymphomas in Europe.
The companies said that the European Union's Committee for Medicinal Products for Human Use has a positive opinion on the treatment of this type of cancer, which begins in the lymphatic system.
The positive opinion from the CHMP is now referred to the European Commission for an approval decision, the companies said.
Write to Sabela Ojea at email@example.com
(END) Dow Jones Newswires